Skip to main content
EQT Logo
EQT logo

Creating next-generation immunotherapies for cancer, infectious, and inflammatory diseases

Developing effective immunotherapies for cancers, inflammatory diseases, and infectious diseases is a major challenge in medical science. Traditional vaccines are slow to develop, often unstable, and have safety and efficacy limitations. A critical issue is addressing inflammation-related pathologies and T cell exhaustion, which hinder effective cancer treatment. What if there was a way to use DNA focused vaccines to effectively help treat diseases?

What is the Solution?

Immuno Cure has developed two innovative solutions to address significant health challenges: a custom DNA vaccine technology and an antibody blocking technology. Their custom DNA vaccine technology involves using a patient's own DNA to create a vaccine that stimulates immune responses more effectively. This method, involving intramuscular injection with electroporation, enhances the delivery and effectiveness of the vaccine, prompting muscle cells to produce specific antigens that boost T cell and B cell responses. This groundbreaking approach is currently being applied in the development of two vaccines, ICVAX for HIV/AIDS and ICCOV for COVID-19, both in clinical trials.

The antibody blocking technology focuses on a particular protein essential for the function of killer T cells in cancer treatment. This solution blocks the interaction of this protein with its receptor, reducing the release of inflammatory molecules and addressing inflammation-related complications. This strategy is key in overcoming T cell exhaustion, a significant barrier in effective tumor treatment. The potential of this technology is currently being assessed for its efficacy in treating cancers such as liver and colorectal cancer.

What EQT Foundation loves about Immuno Cure

EQT Foundation is impressed with the strides Immuno Cure is taking in its contributions to public health, especially in addressing difficult-to-treat diseases. Utilizing a patient's own DNA to effectively administer vaccinations could be a crucial breakthrough for the future of medicine.

ThinQ is the must-bookmark publication for the thinking investor.

Do You Want to Know More?

Get in touch with us and take the first step to successive growth.

Get the Latest Updates

Subscribe to EQT Foundation's press releases and updates.